Every year Roche organizes a world meeting with all its officers. Two days where the pharmaceutical giant meets to visit one of their offices and reflect on their present and future. In 2015 has arrived the moment to visit Roche Sant Cugat, in Barcelona. In this context we must understand the visit of its top leaders to Vall d'Hebron University Hospital and VHIR.During two hours, within a tight schedule of two days, Roche has decided that one of the activities of its annual meeting would be visiting our hospital and research institute. The reason is easy, Vall d'Hebron is one of the leaders of the pharmaceutical in innovative projects in our country, so that's the reason why the responsible for Roche Spain wanted to show their international colleagues the potential of the collaboration with our campus.The meeting has been chaired by the manager of HUVH, Dr. Vicente Martínez Ibáñez, and the head of research and innovation of the Catalan Ministry of Health, Gabriel Capellá. Also, Ramon Maspons, responsible of Innovation of the Health Quality and Evaluation Agency of Catalunya (AQuAS) made a presentation to inform the responsible of Roche about the data indicating the good work being done in our country related to research and innovation.On the part of Roche have been present the senior management of the Leadership Team, Roland Diggelmann, Division COO, Dan Zabrowski, Global Head Tissue Diagnostics and Jean-Claude Gottraux, Global Head Professional Diagnostics, and other regional leaders to complete twenty representatives.As to VHIR, besides its director, Dr. Joan Comella, who presented the hospital and its research, there were researchers from the liver diseases group. Represented by Dr. Josep Quer, presented a unique breakthrough that will serve to develope a new deep sequencing methodology that accurately classifies the 7 confirmed genotypes of the hepatitis C (HCV) virus, and the different subtypes. The new system also allows, for the first time, to identify infections with more than one subtype of the virus (mixed infections), the variability of the virus and possible resistance mutations.On behalf of VHIO, besides the presence of its director, Dr. Josep Tabernero, has intervened Dr. Joaquin Arribas, who presented the possible developments of diagnostic applications based on platforms of new generations of Roche, the basis of RIS3CAT project, in which are jointly working VHIR, VHIO and Roche."It is a pleasure to visit Barcelona and being able to see first hand the full potential of the relationship between Roche and Vall d'Hebron. We were impressed to see what it's being done and what we can do together in the future," said Roland Diggelmann to close the meeting.